This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Patricia R. Hebert, PhD; J. Michael Gaziano, MD, MPH; Charles H. Hennekens, MD, DrPh
Boston, Mass

Arch Intern Med. 1996;156(2):215.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In reply

We agree with Boop and colleagues that newer lipid-lowering drugs (hydroxymethylglutaryl coenzyme A reductase inhibitors or statins) that yield greater reductions in cholesterol raise the possibility of decreased risks of strokes as well as coronary events. In particular, in the recently reported Scandinavian Simvastatin Survival Study, conducted in patients with coronary disease, a significant 30% reduction in risk of stroke was found in the simvastatintreated group compared with the placebo-treated group.¹ The mean percent reduction achieved in total cholesterol in that study was 25%: more than twofold the average 10% reduction achieved in previous trials.

Several other such trials with these agents will be completed in the relatively near future, and systematic overviews of all the data may provide a firm basis for treatment recommendations for lowering the risk of stroke. . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?